Evidence map›Paper›PMID 38441026›Full record

ArticleCurrent gene therapy2024

ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification.

Xiaojuan Ding, Ailing Wan, Xin Qi, Ke'er Jiang, Zhao Liu, Buze Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Current gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Chemoradiotherapy facilitates siglec-10Cancer immunology, immunotherapy : CII · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaojuan DingGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.
Ailing WanGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.
Xin QiGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.
Ke'er JiangGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.
Zhao LiuThe First Clinical Medical College, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.
Buze ChenThe First Clinical Medical College, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.
Xuzhou Medical College · CNSecond People’s Hospital of Huai’an · CN

Funding

Xuzhou Key R&D Program ZYSB20210489
6 · The paper itself

Abstract

backgroundThe role of Zinc Finger Protein 695 (ZNF695) is unclear in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC).

objectiveThe objective of this study was to conduct a comprehensive analysis and experimental validation of ZNF695 in CESC.

methodsThe study investigated the expression of ZNF695 in both pan-cancer and CESC, utilizing data from The Cancer Genome Atlas (TCGA) database to assess its diagnostic value. The present study investigated the association between ZNF695 expression levels and clinical characteristics, as well as prognosis, in patients with CESC. The study explored potential regulatory networks involving ZNF695, including its association with immune infiltration, immune score, stemness index based on mRNA expression (mRNAsi), and drug sensitivity in CESC. We explored the expression of ZNF695 in CESC single cells. ZNF695 expression was validated using GSE29570.

resultsZNF695 was found to be aberrantly expressed in pan-cancer and CESC. There was a significant correlation observed between an elevated level of ZNF695 expression in patients with CESC and histological grade (p = 0.017). Furthermore, a strong association was found between high ZNF695 expression in CESC patients and poorer overall survival (OS) (HR: 1.87; 95% CI: 1.17-3.00; p = 0.009), Progression-free Survival (PFS) (HR: 1.86; 95% CI: 1.16-2.98; p = 0.010), and Disease-specific Survival (DSS) (HR: 1.98; 95% CI: 1.15-3.42; p = 0.014). The expression of ZNF695 in CESC patients (p = 0.006) was identified as an independent prognostic determinant. ZNF695 was associated with steroid hormone biosynthesis, oxidative phosphorylation, and so on. ZNF695 expression correlated with immune infiltration, immune score, and mRNAsi in CESC. ZNF695 expression significantly and negatively correlated with AICA ribonucleotide, BIX02189, QL-XI-92, STF-62247, and SNX-2112 in CESC. ZNF695 gene was upregulated in CESC tissues and cell lines. ZNF695 was significantly upregulated in the CESC cell lines.

conclusionZNF695 may be a potential prognostic biomarker and immunotherapeutic target for CESC patients.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellComputational BiologyUterine Cervical NeoplasmsAdenocarcinomaFemaleGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorCervical squamous cell carcinomadrug sensitivityendocervical adenocarcinomaimmune infiltrationprognosistherapy target.ZNF695

Identifiers

PMID38441026
OpenAlexW4392471336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.